OncoMatch/Clinical Trials/NCT07481058
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Is NCT07481058 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for esophageal squamous cell carcinoma (escc).
Treatment: KC1036 · Toripalimab · Paclitaxel · Cisplatin · KC1036 — The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Metastatic disease required
Patients who have not received prior systemic anti-tumor therapy for the current recurrent or metastatic disease; At least one measurable tumor lesion according to RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-angiogenic drug
Prior therapy with anti-angiogenic drugs
Cannot have received: immunotherapy
Prior therapy with ... immunotherapy
Cannot have received: systemic therapy
Systemic therapy ... within 4 weeks prior to the first dose
Cannot have received: investigational drug
investigational drugs ... within 4 weeks prior to the first dose
Cannot have received: live vaccine
live vaccines within 4 weeks prior to the first dose
Cannot have received: radiation therapy
Palliative radiotherapy within 2 weeks
Cannot have received: surgery
major surgery within 28 days prior to enrollment
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify